|*Seminar Series:||IMB Seminar Series|
|*Location:||QBP Auditorium, Bld 80|
Speaker #1 details
|*Title of talk:||Oral equivalents of antibody drugs: the pathway to an Au$119M Nasdaq listing|
|*Speaker's name:||A/Prof Mark Smythe|
|*Speaker's organisation:||Protagonisty Pty Ltd & Institute for Molecular Bioscience, UQ|
|Talk Abstract:||Protagonist Therapeutics is a 15-year "overnight success", having recently undergone an oversubscribed Au$119M primary Nasdaq listing. In this presentation, I will outline the science and business evolution of the company from a technology-based start-up founded at The University of Queensland to what could be considered a global biotechnology company.
Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities (NCEs). Our primary focus is on developing first-in-class oral peptide drugs that specifically target biological pathways also targeted by currently marketed injectable antibody drugs. Compared to injectable antibody drugs, our oral peptides offer targeted delivery to the diseased gastrointestinal (GI) tissue, the potential for improved safety due to minimal exposure in the blood and minimal systemic target blockade, improved convenience and compliance due to oral delivery. Our initial lead product candidates, PTG-100 and PTG-200, are orally delivered peptides with these advantages, and we believe they have the potential to transform the existing treatment paradigm for Inflammatory Bowel Disease and provide patients with significant longer term remission.
|Speaker's bio:||Mark Smythe, Ph.D.—Mark has over 25 years experience in the biotechnology sector. He has been involved in transitioning technology focused start-up companies to product based international enterprises and has been involved in the development of one marketed drug and several clinical candidates. He is Founder of Protagonist Therapeutics, which was Australia's Biotechnology company of the year in 2016. Mark has significant commercial research experience and has worked with companies such as, Zealand Pharma, Ironwood Pharmaceuticals, Wellcome, Glaxo, GlaxoWellcome, GlaxoSmithKline, Novo Nordisk, AstraZeneca, and Shisheido. He is also a Group Leader at the Institute for Molecular Bioscience, The University of Queensland. Prior to Protagonist, he was Principal Investigator at the Centre for Drug Design and Development. Mark earned a Ph.D. in Medicinal Chemistry from Melbourne University and a B.Sc (Hons) in Synthetic Organic Chemistry from James Cook University.|
Speaker #2 details
|*Title of talk:|
|*Host name:||Professor Matt Sweet|
|Host phone number:||62082|